NF2 Clinical Trial

In 2012 House Research Institute will sponsor a three-year, Phase II clinical trial, evaluating the efficacy of the drug RAD001 (otherwise known as everolimus). Following an identical protocol, the clinical trial will be conducted simultaneously in Los Angeles, California, and Paris, France. In Los Angeles, the trial will be under the direction of Dr. Giovannini. Find more information here at clinicaltrials.gov (Indentifier #NCT01345136).